PRPO (Precipio) Valuation Rank

View and export this data going back to 2000. Start your Free Trial

What is Precipio Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

Three factors:
- Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
- Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
- Industry relative valuation
Companies without enough data is not ranked
Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Precipio Valuation Rank Related Terms

Thank you for viewing the detailed overview of Precipio's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Precipio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Precipio Inc (NAS:PRPO) » Definitions » Valuation Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

4 Science Park, New Haven, CT, USA, 06511

Website

https://www.precipiodx.com

Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.

Executives

Richard A Sandberg	director	330 NEVEDA STREET, NEWTON MA 02460-1458
Ahmed Zaki Sabet	officer: Chief Operations Officer	33 ANDYS DR, EAST HAVEN CT 06512
Ilan Danieli	director, officer: Chief Executive Officer	14707 CALIFORNIA STREET, SUITE 5, OMAHA NE 68154
Matthew Gage	officer: Chief Financial Officer	56 STAGECOACH CIRCLE, MILFORD CT 06460
David Seth Cohen	director, 10 percent owner	C/O STANDARD OIL, 299 BISHOP AVENUE, BRIDGEPORT CT 06610
Ronald Asbury Andrews	director	5791 VAN ALLEN WAY, CARLSBAD CA 92008
Randal J Kirk	10 percent owner	1881 GROVE AVENUE, RADFORD VA 24141
Kathleen Laporte	director
Robert Patzig	director	THE GOVERNOR TYLER, 1881 GROVE AVENUE, RADFORD VA 24141
Michael A Luther	director	21 CORPORATE CIRCLE, ALBANY NY 12203
Jeffrey Cossman	director	C/O PRECIPIO INC., 4 SCIENCE PARK, NEW HAVEN CT 06511
Samuel D Riccitelli	director	2850 FRONTIER DR., WARSAW IN 46582
Carl Iberger	officer: Chief Financial Officer	C/O PRECIPIO, INC., 12325 EMMET STREET, OMAHA NE 68164
Douglas Fisher	director	587 PATROL RD, WOODSIDE CA 94062
Mark Rimer	director, 10 percent owner	C/O PRECIPIO, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511